Tagged as: Fresenius Kabi

Commercialization of Ustekinumab and Golimumab Biosimilars

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab biosimilars in Southeast Asia.  Bio-Thera will develop, manufacture, and supply BAT2206 (the proposed ustekinumab biosimilar referencing Janssen’s STELARA) and BAT2506 (the proposed golimumab biosimilar referencing Janssen’s…

Read More

Amgen and Celltrion Settle Denosumab BPCIA Case

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding Celltrion’s denosumab biosimilar, CT-P41.  Pursuant to the agreement, Celltrion will be enjoined from making, using, selling,…

Read More